Effect of LS 1727, a nitrosocarbamate of 19-nortestosterone, on the R-3327 rat prostatic adenocarcinoma.
LS 1727, a nitrosocarbamate of 19-nortestosterone did not affect the growth of the androgen-dependent R-3327 rat prostate adenocarcinoma. Such treatment markedly increased the weight of the ventral prostate and reduced body weight. The androgenic character of LS 1727 was demonstrated in an experiment in which LS 1727 was found to reduce the uptake of tritiated dihydrotestosterone in both the ventral prostate and the tumors. The androgenic growth-stimulating action of LS 1727 on the tumors may have counteracted the cytostatic, growth-inhibitory action of the compound.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000378:metabolism; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats
D000970:Antineoplastic Agents; D013196:Dihydrotestosterone; C019508:19-nortestosterone nitrosocarbamate; D009277:Nandrolone